This transaction
The acquisitionThe voting-rights ratio is the share of the votes exercisable at a shareholders’ meeting that will be held after this transaction.The percentage before the change is not stated in this document.
Research and development and manufacture of biodegradable balloon rectal spacers for prostate cancer
Currently under review
| Item | Details |
|---|---|
| Transaction name | The acquisition |
| Name of the Subject Company | BioProtect Ltd. |
| Business Description of the Subject Company | Research and development and manufacture of biodegradable balloon rectal spacers for prostate cancer |
| Location of the Subject Company | Netanya, Israel |
| Capital Stock of the Subject Company | ¥11,451 million (as of 31 December 2025) |
| Date of Establishment of the Subject Company | 22 September 2004 |
| Net Sales of the Subject Company | ¥2,329 million (fiscal year ended December 2025) |
| Operating Profit of the Subject Company | ¥2,589 million loss (fiscal year ended December 2025) |
| Net Income of the Subject Company | ¥4,737 million net loss (fiscal year ended December 2025) |
| Net Assets of the Subject Company | ¥2,099 million negative net assets (fiscal year ended December 2025) |
| Acquisition price | $270 million (approximately ¥43.3 billion) |
| Number of shares acquired | 16,925,621 shares (number of voting rights: Not disclosed) |
| Voting rights ownership percentage | After 100% (before not disclosed) |
| Impact on Business Performance | Currently under review |
| Contract Date | 26 May 2026 |
| Execution Date / Effective Date | 1 June 2026 (予定) |
Items this document does not state (16)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The acquisition is intended to strengthen Olympus's ability to address unmet needs in cancer treatment, including prostate cancer, by focusing on the urology field and incorporating BioProtect's biodegradable balloon rectal spacer technology, expand its portfolio in adjacent therapeutic areas including gastroenterology and urology, and enhance the value it provides across the entire care pathway.